Peptic ulcer disease (Q55898008)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28242110 AND SRC:MED&resulttype=core&format=json

3 April 2020

title

Peptic ulcer disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28242110 AND SRC:MED&resulttype=core&format=json

3 April 2020

language of work or name

English

0 references

publication date

25 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28242110 AND SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28242110 AND SRC:MED&resulttype=core&format=json

3 April 2020

volume

390

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28242110 AND SRC:MED&resulttype=core&format=json

3 April 2020

issue

10094

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28242110 AND SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

613-624

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28242110 AND SRC:MED&resulttype=core&format=json

Prevalence and incidence of peptic ulcer disease in a Danish County--a prospective cohort study

3 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Review article: historic changes of Helicobacter pylori-associated diseases

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Time trends of ulcer mortality in Europe

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Time trends of ulcer mortality in non-European countries

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Time trends in upper gastrointestinal diseases and Helicobacter pylori infection in a multiracial Asian population--a 20-year experience over three time periods

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

The changing face of hospitalisation due to gastrointestinal bleeding and perforation.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

We Are Using Too Many PPIs, and We Need to Stop: A European Perspective

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

The association of vacA genotype and Helicobacter pylori-related disease in Latin American and African populations.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Pathogenesis and therapy of gastric and duodenal ulcer disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Helicobacter pylori virulence and cancer pathogenesis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Helicobacter pylori-induced gastric inflammation and gastric cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Association of Helicobacter pylori babA2 with peptic ulcer disease and gastric cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Effects of IL-1β on the proliferation and apoptosis of gastric epithelial cells and acid secretion from isolated rabbit parietal cells

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Interleukin-1 polymorphisms associated with increased risk of gastric cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Association between TNF α gene polymorphisms and the risk of duodenal ulcer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Polymorphisms in TLR9 but not in TLR5 increase the risk for duodenal ulcer and alter cytokine expression in the gastric mucosa.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Identification of genetic loci associated with Helicobacter pylori serologic status

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Burden of nonsteroidal anti-inflammatory and antiplatelet drug use in Asia: a multidisciplinary working party report

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Risk of upper gastrointestinal bleeding from different drug combinations

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Association of PSCA rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Review article: Helicobacter pylori-negative duodenal ulcer disease.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Hemorrhagic gastric and duodenal ulcers after the Great East Japan Earthquake Disaster

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Accommodation in a refugee shelter as a risk factor for peptic ulcer bleeding after the Great East Japan Earthquake: a case-control study of 329 patients

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Helicobacter-negative gastritis: polymerase chain reaction for Helicobacter DNA is a valuable tool to elucidate the diagnosis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

The effect of environmental pH on the proton motive force of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Inhibition of carbachol stimulated acid secretion by interleukin 1beta in rabbit parietal cells requires protein kinase C

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

H. pylori acutely inhibits gastric secretion by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Helicobacter pylori infection and chronic gastric acid hyposecretion

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Determinants of the short-term gastric damage caused by NSAIDs in man.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Intestinal permeability and inflammation in patients on NSAIDs

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Gastrointestinal effects of aspirin

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Mucosal Repair and COX-2 Inhibition

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-negative ulcer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Value of the "Test & Treat" Strategy for Uninvestigated Dyspepsia at Low Prevalence Rates of Helicobacter pylori in the Population.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

The Toronto Helicobacter pylori Consensus in Context

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Role of bismuth in improving Helicobacter pylori eradication with triple therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Optimum duration of regimens for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Sequential versus standard triple first-line therapy forHelicobacter pylorieradication

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014).

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Summing the risk of NSAID therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Risk factors associated with refractory peptic ulcers

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Transfusion strategies for acute upper gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Multicentre comparison of the Glasgow Blatchford and Rockall Scores in the prediction of clinical end-points after upper gastrointestinal haemorrhage.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Challenges in the management of acute peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Prokinetics in acute upper GI bleeding: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Outcome of endoscopic treatment for peptic ulcer bleeding: Is a second look necessary? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

The Helicobacter Eradication Aspirin Trial (HEAT): A Large Simple Randomised Controlled Trial Using Novel Methodology in Primary Care.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(16)32404-7

7 January 2021

10.1016/S0140-6736(16)32404-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28242110 AND SRC:MED&resulttype=core&format=json

3 April 2020

1 reference